comparemela.com

Page 10 - Johnt Treace News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Treace Medical Concepts Reports First Quarter 2022 Financial Results

Treace Medical Concepts Reports First Quarter 2022 Financial Results
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

MidCap Financial Provides $150MM Debt Financing to Treace Medical Concepts - News

Treace Medical Concepts entered into a new five-year $150 million loan arrangement with MidCap Financial, comprising up to $120 million in term loans and a $30 million revolving credit facility. Proceeds from the new term loan refinanced the Company’s existing $30 million term loan from CR Group LP. In addition, the new revolving credit facility.

Treace Medical Concepts : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K

Treace to Present at the 40th Annual J P Morgan Healthcare Conference on Wednesday, January 12, 2022

07.01.2022 - PONTE VEDRA, Fla., Jan. 07, 2022 (GLOBE NEWSWIRE) - Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known .

Treace Medical Concepts Reports First Quarter 2021 Financial Results

Message : Required fields PONTE VEDRA, Fla., May 25, 2021 (GLOBE NEWSWIRE) Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2021. Recent Highlights: Revenue of $18.7 million, a 66% increase over the same period last year Gross margin of 82.2%, an increase of 340 basis points from the same period last year Completed initial public offering with $107.1 million in proceeds, net of underwriting discounts, commissions and offering costs Interim results from ALIGN3D™ clinical study demonstrating positive radiographic and patient-reported outcomes starting at 6 weeks and maintained at 12 months

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.